Financial Performance - Operating revenue for Q1 2023 was CNY 58,924,811.64, representing a year-on-year decline of 32.79%[11] - Net profit attributable to shareholders for Q1 2023 was CNY 5,623,307.50, down 63.17% from the same period last year[11] - The basic earnings per share for Q1 2023 was CNY 0.07, down 74.07% compared to the same period last year[12] - Gross profit for Q1 2023 was ¥10,723,546.57, down from ¥26,070,163.09 in Q1 2022, indicating a decrease of about 58.8%[45] - Net profit for Q1 2023 was ¥5,688,786.31, compared to ¥15,268,841.14 in Q1 2022, reflecting a decline of approximately 62.7%[46] - The total comprehensive income for Q1 2023 was ¥5,688,786.31, down from ¥15,268,841.14 in Q1 2022, reflecting a decrease of about 62.7%[47] Cash Flow and Assets - The company reported a net cash flow from operating activities of -CNY 19,892,433.69, a decrease of 166.96% compared to the previous year[11] - Cash and cash equivalents were reported at CNY 126,529,528.29, compared to CNY 192,703,332.20 in the previous period, representing a significant decline of approximately 34.3%[33] - Operating cash flow for Q1 2023 was negative at -¥19,892,433.69, contrasting with a positive cash flow of ¥29,708,153.56 in Q1 2022[48] - The total cash and cash equivalents at the end of the period stood at $126.19 million, down from $15.76 million previously[51] Revenue and Sales - The average selling price of quercetin decreased by 46.88% from CNY 823,600 per ton to CNY 437,500 per ton, contributing to the revenue decline[13] - The sales revenue of Diosmin increased by 19.53% year-on-year, while the sales revenue of Berberine increased by 97.34%[14] - The total revenue for the company reached 57,997,891, representing a 76.67% increase compared to the previous period[21] Assets and Liabilities - Total assets as of March 31, 2023, were CNY 430,779,352.64, a decrease of 2.20% compared to the end of 2022[11] - The company's total liabilities decreased to CNY 34,817,293.65 from CNY 50,225,567.49, marking a reduction of about 30.5%[35] - The total equity attributable to shareholders increased to CNY 395,962,058.99 from CNY 390,247,751.40, reflecting a growth of approximately 1.8%[35] - The company's current assets totaled CNY 356,806,508.56, down from CNY 378,983,354.45, indicating a decrease of about 5.83%[33] Commitments and Compliance - The company has confirmed that there are no ongoing litigation or arbitration matters during the reporting period[24] - The company has maintained compliance with all regulatory requirements during the reporting period[24] - The actual controller has committed to not engaging in competitive activities with the company, and this commitment is currently being fulfilled[25] - The company is committed to implementing measures to stabilize stock prices as approved by the shareholders' meeting within three years post-listing[26] Research and Development - Research and development expenses increased to CNY 3,482,350.98 in Q1 2023 from CNY 3,082,665.80 in Q1 2022, reflecting a growth of 13%[42] - The company plans to focus on market expansion and new product development in the upcoming quarters[40] - The company plans to enhance its quercetin production capacity through automation and continuous R&D efforts, which are expected to increase sales in the future[14]
欧康医药(833230) - 2023 Q1 - 季度财报